YU26700A - Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin - Google Patents

Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin

Info

Publication number
YU26700A
YU26700A YU26700A YUP26700A YU26700A YU 26700 A YU26700 A YU 26700A YU 26700 A YU26700 A YU 26700A YU P26700 A YUP26700 A YU P26700A YU 26700 A YU26700 A YU 26700A
Authority
YU
Yugoslavia
Prior art keywords
cis
phenoksy
tetrahydronaphtalen
pheniyl
etil
Prior art date
Application number
YU26700A
Other languages
English (en)
Inventor
Charles Kwok-Fung Chiu
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of YU26700A publication Critical patent/YU26700A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/215—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/48—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation involving decarboxylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/56—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds
    • C07C45/57—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom
    • C07C45/59—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom in five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/22—Radicals substituted by singly bound oxygen or sulfur atoms etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/26—Radicals substituted by doubly bound oxygen or sulfur atoms or by two such atoms singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Ovaj pronalazak obezbedjuje poboljšani postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4-tetrahidronaftalen-1-il)fenoksi)etil)pirolidin koji je intermedijer za dobijanje (-)cis-6-fenil-5-(4-(2-pirolidin-1-il-etoksi)fenil)-5,6,7,8-tetrahidronaftalen-2-ola koji je koristan u tretmanu osteoporoze.[This invention an improved process for cis-1-(2-(4-(6-metoxy-2-pheniyl-1,2,3,4-tetrahydronaphtalen-1-yl)phenoksy)etil)pyrrolidin which is an intermediate for the preparation of (-)cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)phenyl)-5,6,7,8-tetrahydronaphthalene-2-ol which is useful for the treatment of osteoporosis.
YU26700A 1999-05-24 2000-05-08 Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin YU26700A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13557899P 1999-05-24 1999-05-24

Publications (1)

Publication Number Publication Date
YU26700A true YU26700A (sh) 2002-06-19

Family

ID=22468706

Family Applications (1)

Application Number Title Priority Date Filing Date
YU26700A YU26700A (sh) 1999-05-24 2000-05-08 Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin

Country Status (25)

Country Link
US (3) US6232476B1 (sh)
EP (1) EP1055658B1 (sh)
JP (2) JP3296809B2 (sh)
KR (1) KR100388176B1 (sh)
CN (3) CN1280128A (sh)
AR (1) AR035990A1 (sh)
AT (1) ATE234269T1 (sh)
AU (1) AU769690B2 (sh)
BR (1) BR0001813B1 (sh)
CA (1) CA2308922C (sh)
DE (1) DE60001599T2 (sh)
DK (1) DK1055658T3 (sh)
ES (1) ES2191597T3 (sh)
HK (1) HK1061843A1 (sh)
HU (1) HUP0001988A3 (sh)
ID (1) ID26146A (sh)
IL (1) IL136231A (sh)
IN (1) IN188849B (sh)
PL (1) PL340237A1 (sh)
PT (1) PT1055658E (sh)
RU (1) RU2195445C2 (sh)
TR (1) TR200001476A2 (sh)
TW (1) TWI231295B (sh)
YU (1) YU26700A (sh)
ZA (1) ZA200002514B (sh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU26700A (sh) * 1999-05-24 2002-06-19 Pfizer Products Inc. Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin
EP1487790B1 (en) * 2002-03-28 2010-03-03 Pfizer Products Inc. Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
JP5212931B2 (ja) * 2006-01-26 2013-06-19 学校法人東京理科大学 ラソフォキシフェン及びその類縁体の製造方法
CZ2007373A3 (cs) * 2007-05-29 2008-12-10 Zentiva, A. S Zpusob prípravy lasofoxifenu
CN102424661A (zh) * 2011-10-21 2012-04-25 南开大学 一种偶氮类色素半抗原与人工抗原的合成方法
CN103113323B (zh) * 2013-02-05 2015-11-11 南京华威医药科技开发有限公司 酒石酸拉索昔芬中间体的制备方法
JP6892151B2 (ja) 2016-10-11 2021-06-23 デューク ユニバーシティ Ｅｒ＋乳がんのラソフォキシフェン処置
EP3773524A4 (en) 2018-04-10 2021-12-22 Duke University TREATMENT OF BREAST CANCER WITH LASOFOXIFEN
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274213A (en) * 1961-09-05 1966-09-20 Upjohn Co Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes
US3234090A (en) 1962-09-10 1966-02-08 Ciba Geigy Corp Pharmaceutical compositions comprising saturated basic ethers
US3522319A (en) 1964-01-23 1970-07-28 Ciba Geigy Corp Phenol substituted tetrahydronaphthalenes useful as estrogenics
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5552241A (en) * 1995-05-10 1996-09-03 Electrochemical Systems, Inc. Low temperature molten salt compositions containing fluoropyrazolium salts
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
YU26700A (sh) * 1999-05-24 2002-06-19 Pfizer Products Inc. Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin

Also Published As

Publication number Publication date
JP2002205990A (ja) 2002-07-23
CA2308922C (en) 2007-05-01
US6395911B1 (en) 2002-05-28
IL136231A (en) 2005-06-19
CA2308922A1 (en) 2000-11-24
JP2000327670A (ja) 2000-11-28
ZA200002514B (en) 2002-02-22
IN188849B (sh) 2002-11-09
PL340237A1 (en) 2000-12-04
ID26146A (id) 2000-11-30
PT1055658E (pt) 2003-07-31
ES2191597T3 (es) 2003-09-16
JP3600206B2 (ja) 2004-12-15
HK1061843A1 (en) 2004-10-08
ATE234269T1 (de) 2003-03-15
EP1055658A3 (en) 2000-12-13
HUP0001988A2 (en) 2001-03-28
AU769690B2 (en) 2004-01-29
CN1280128A (zh) 2001-01-17
KR20010029733A (ko) 2001-04-16
CN1271030C (zh) 2006-08-23
AU3636200A (en) 2000-11-30
US6323345B1 (en) 2001-11-27
AR035990A1 (es) 2004-08-04
KR100388176B1 (ko) 2003-06-19
JP3296809B2 (ja) 2002-07-02
TWI231295B (en) 2005-04-21
CN1226265C (zh) 2005-11-09
DE60001599D1 (de) 2003-04-17
CN1502598A (zh) 2004-06-09
CN1502597A (zh) 2004-06-09
IL136231A0 (en) 2001-05-20
HUP0001988A3 (en) 2002-04-29
EP1055658B1 (en) 2003-03-12
DE60001599T2 (de) 2003-11-13
US6232476B1 (en) 2001-05-15
HU0001988D0 (en) 2000-08-28
US20020042524A1 (en) 2002-04-11
BR0001813B1 (pt) 2011-03-22
DK1055658T3 (da) 2003-04-22
BR0001813A (pt) 2001-01-02
TR200001476A2 (tr) 2001-02-21
RU2195445C2 (ru) 2002-12-27
EP1055658A2 (en) 2000-11-29

Similar Documents

Publication Publication Date Title
YU64100A (sh) Postupak za sintetizovanje cox-2 inhibitora
IL189358A0 (en) Novel process for the synthesis of 5 - (4 - fluorophenyl) - 1 - [2 - ((2r, 4r)- 4 - hydroxy - 6 - oxo -tetrahydro - pyran - 2 - yl) - ethyl] - 2 - isopropyl- 4 - phenyl - 1h - pyrrole - 3 - carboxylic acid phenylamide
GB0111523D0 (en) Chemical compounds
DE60012751D1 (de) Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz
MY131518A (en) 6-substituted pyrido-pyrimidines
AU1074702A (en) Sulfamides as gamma-secretase inhibitors
IL152586A0 (en) Serine protease inhibitors
MXPA04003516A (es) Derivados de 4-(4-alcoxi-3-hidroxifenil)-2-pirrolidona como inhibidores de pde-4 para el tratamiento de sindromes neurologicos.
YU26700A (sh) Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin
IL197642A0 (en) Heterocyclic derivatives as opioid modulators
TR200302288T2 (tr) Terapi için yeni bileşikler ve metotlar.
DE69715173D1 (en) Bisarylcyclobutenderivate als cyclooxygenasehemmer
ATE390134T1 (de) (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4- fluorophenyl)ethyl)-4-piperidinemethanol oder prodrug davon zur behandlung von demenzsymptomen oder kognitiven störungen
RS20050105A (en) Process for preparing 5-(4-(54) fluorophenyl)-1-(2-((2r,4r)-4- hydroxy -6-oxo-tetrahydro-pyran-2-yl)ethyl)- 2-isopropyl-4- phenyl-1h-pyrrole-3- carboxylic acid phenylamide
MX9701569A (es) Pirimidin(tio)onas substituidas.
NZ535169A (en) Process for making chiral 1,4-disubstituted piperazines
HRP970289A2 (en) Process for preparing phenyl heterocycles useful as cox-2 inhibitors
YU22802A (sh) Izonipekotamidi za lečenje poremećaja nastalih posredstvom integrina
MXPA03001272A (es) Procedimiento para la preparacion de dinapsolina.
RS20050760A (sr) Postupak za izradu fenilamida 5-(4- fluorofenil)-1-(2-((2r, 4r)-4-hidroksi- 6-okso-tetrahidro-piran-2-il)etil)-2- izopropil-4-fenil-1h-pirol-3- karboksilne kiseline
MXPA04005176A (es) N-ureido-piperidinas como antagonistas viii para receptores ccr-3.
UA74426C2 (uk) Фенілпіперазини
MXPA03009723A (es) Procedimientos e intermediarios para preparar epoxidos substituidos de bencilo.
CA2555035A1 (en) Process for cis-1-{2-[4-(6-methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy]ethyl}pyrrolidine
WO2002036546A3 (en) Alkynyl amides and their therapeutic applications